本帖最后由 老马 于 2013-3-13 13:43 编辑
0 b% d) _; H6 t' d$ T1 A
A0 A U! U! N; |' z0 _8 N& ^0 v' L健择(吉西他滨)+顺铂+阿瓦斯汀5 g9 D: R% _: M; g
Gemzar +Cisplatin + Avastin9 p) X- X W( h
http://annonc.oxfordjournals.org/content/21/9/1804.full' Q% x4 k: \. b3 w
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
6 n% ]3 v) N# n3 z: g. i$ cPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ; A1 Y; `, E* B, O+ J$ X
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 [7 S, }' p9 n' i9 v
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 973)
( z% b. _: x. i N; d- `华为网盘附件:
1 \! Q: U+ h& j a4 G* R; n【华为网盘】ava.JPG* m& \2 j3 x3 l! w
|